13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000200406
Total reported value
$798.7M
$798.7M
17 檔
60.0%
According to the latest 13F quarterly dataset, Johnson & Johnson managed an equity portfolio of $798.7M at the end of Q4 2025, spanning 17 distinct U.S. exchange-listed positions.
In Q4 2025, Johnson & Johnson adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 5 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including PTGX, NBTX, RAPP) accounted for 60.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
VOR
市值: $702.8K
Top Position Liquidated / Trimmed
ARWR
前期市值: $8.5M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 38.54% | -1.98% | — | |
| 2 | NBTX | Nanobiotix SA - Adr | Stock-Other | 23.43% | -0.06% | — | |
| 3 | RAPP | Rapport Therapeutics Inc | Stock-Other | 9.75% | +0.75% | — | |
| 4 | MGTX | MeiraGTx Holdings plc | Stock-Other | 9.51% | +2.41% | — | |
| 5 | CVRX | Cvrx Inc | Stock-Other | 5.15% | -3.25% | -1.91% | |
| 6 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 4.08% | +0.10% | — | |
| 7 | LEGN | Legend Biotech Corp-adr | Stock-Other | 3.19% | +0.69% | — | |
| 8 | XNCR | Xencor Inc | Stock-Other | 2.06% | +0.13% | — | |
| 9 | PRCT | Procept Biorobotics CORP | Stock-Other | 2.03% | -0.36% | — | |
| 10 | FATE | Fate Therapeutics Inc | Stock-Other | 0.60% | +0.52% | — | |
| 11 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.60% | -0.16% | — | |
| 12 | ✓ | Rallybio CORP | Stock-Other | 0.45% | — | — | |
| 13 | LYEL | Lyell Immunopharma Inc | Stock-Other | 0.30% | — | — | |
| 14 | VOR | Vor Biopharma Inc | Stock-Other | 0.13% | -0.03% | — | |
| 15 | NNOX | Nano-X Imaging Ltd. | Stock-Other | 0.08% | -0.03% | EXIT | |
| 16 | LAB | Standard Biotools Inc | Stock-Other | 0.07% | -0.01% | — | |
| 17 | ACET | Adicet Bio Inc | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | +6.3% | — | Unchanged |
| 2 | NBTX | Nanobiotix SA - Adr | +2.4% | — | Unchanged |
| 3 | XNCR | Xencor Inc | +0.3% | — | Unchanged |
| 4 | LYEL | Lyell Immunopharma Inc | +0.1% | — | Unchanged |
| 5 | ✓ | Rallybio CORP | +0.1% | — | Unchanged |
| 6 | LAB | Standard Biotools Inc | 0% | — | Unchanged |
| 7 | NNOX | Nano-X Imaging Ltd. | 0% | — | Unchanged |
| 8 | NMRA | Neumora Therapeutics Inc | -0.1% | — | Unchanged |
| 9 | FATE | Fate Therapeutics Inc | -0.2% | — | Unchanged |
| 10 | PRCT | Procept Biorobotics CORP | -0.5% | — | Unchanged |
| 11 | CTNM | Contineum Therapeutics Inc-a | -0.5% | — | Unchanged |
| 12 | RAPP | Rapport Therapeutics Inc | -0.8% | — | Unchanged |
| 13 | MGTX | MeiraGTx Holdings plc | -1.3% | — | Unchanged |
| 14 | CVRX | Cvrx Inc | -1.4% | -1.91% | Trim |
| 15 | LEGN | Legend Biotech Corp-adr | -2.1% | — | Unchanged |
| 16 | ARWR | Arrowhead Pharmaceuticals In | — | EXIT | Sold out |
| 17 | VOR | Vor Biopharma Inc. | — | EXIT | Sold out |
| 18 | VOR | Vor Biopharma Inc | — | NEW | New buy |
| 19 | TORCEUR | Adicet Bio Inc | — | EXIT | Sold out |
| 20 | ACET | Adicet Bio Inc | — | NEW | New buy |
| 21 | ✓ | Biomx Inc | — | EXIT | Sold out |
| 22 | SENS1GBP | Senseonics Holdings Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Johnson & Johnson reported a total U.S. public equity portfolio value of $798.7M across 17 disclosed positions in Q4 2025.
During Q4 2025, Johnson & Johnson's top holdings by market value included PTGX (38.5%)、NBTX (23.4%)、RAPP (9.8%). The largest single position, PTGX, represented 38.5% of total portfolio value.
In Q4 2025, Johnson & Johnson made 8 total portfolio adjustments, initiating 2 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.